The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast

Cancer

Volumn 80, Issue 4, 1997, Pages 732-740

  Wazer, David E ^a,c   Morr, Jody ^a   Erban, John K ^a   Schmid, Christopher H ^a   Ruthazer, Robin ^a   Schmidt Ullrich, Rupert K ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Breast conservation; Cosmesis; Local control; Radiotherapy; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONSERVATIVE TREATMENT; ESTHETICS; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ESTHETICS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0030743445     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970815)80:4<732::AID-CNCR12>3.0.CO;2-U     Document Type: Article

References (31)

1. Wazer DE, DiPetrillo T, Schmidt-Ullrich R, Weld L, Smith TJ, Marchant DJ, et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early stage breast carcinoma. J Clin Oncol 1992; 10:356-63.
2. Schmidt-Ullrich R, Wazer DE, DiPetrillo T, Marchant D, Smith TJ, Safaii H, et al. Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor-bearing quadrant. Int J Radiat Oncol Biol Phys 1993; 27:545-52.
3. Schmidt-Ullrich R, Wazer D, Tercilla O, Safaii H, Marchant DJ, Smith TJ, et al. Tumor margin assessment as a guide to optimal conservation surgery and irradiation in early stage breast carcinoma. Int J Radiat Oncol Biol Phys 1989;17:733-8.
4. Wazer DE, Sinesi M, Schmidt-Ullrich R, Smith TJ, Safaii H, Marchant DJ, et al. Importance of surgical and pathological determinants of tumor margin status for breast conservation therapy. Breast Dis 1991;4:285-92.
5. Schnitt S, Connolly J, Harris JR, Hellman S, Cohen RB. Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer 1984;53:1049-57.
6. Zwicker RD, Schmidt-Ullrich R, Schiller B. Planning of Ir-192 seed implants for boost irradiation to the breast. Int J Radiat Oncol Biol Phys 1985;11:2163-70.
7. Wazer DE, Erban J, Robert NJ, Smith TJ, Marchant DJ, Schmid C, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer 1994;74:878-83.
8. Osborne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 1983; 43:3583-5.
9. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989;7:710-7.
10. Sinclair WK. Cyclic X-ray responses in the mammalian cells in vitro. Radiat Res 1968;33:620-33.
11. Wazer DE, Tercilla OF, Lin PS, Schmidt-Ullrich R. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17beta-estradiol and tamoxifen. Br J Radiol 1989;62:1079-83.
12. Wazer DE, Joyce M, Chan W, Gewirtz D, Lin PS, Solares G, et al. Effects of tamoxifen on the radiosensitivity of hormonally responsive and unresponsive breast carcinoma cells. Radiat Oncol Invest 1993;1:20-8.
13. Blazek ER, Graybill J. Tamoxifen both radiosensitizes and increases DNA initial double-strand break yield in MCF-7, but not MDA MB-231, breast cancer cells. Int J Radiat Oncol Biol Phys 1994;30(Suppl):307.
14. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990;62:405-9.
15. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;313:745-7.
16. Jordan VC. Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer. Cancer 1993;72:1-2.
17. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
18. Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor beta-1 expression in irradiated liver. Radiat Res 1990; 122:77-85.
19. Geraci JP, Mariano MS. Radiation hepatology of the rat: parenchymal and non-parenchymal cell injury. Radiat Res 1993;136:205-13.
20. Martin M, Lefaix JL, Pinton P, Crechet F, Daburon F. Temporal modulation of TGF-betal and beta-actin gene expression in the pig skin and muscular fibrosis after ionizing radiation. Radiat Res 1993;134:63-70.
21. Langberg CW, Hauer-Jensen M, Sung CC, Kane CJ. Expression of fibrogenic cytokines in rat small intestine after fractionated irradiation. Radiother Oncol 1994;32:29-36.
22. Barcellos-Hoff MH, Dernyck R, Tsang ML, Weatherbee JA. Transforming growth factor beta activation in irradiated murine mammary gland. J Clin Invest 1994;93:892-9.
23. Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 1996;35:669-77.
24. Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Randomized trial of adjuvant tamoxifen in node negative post-menopausal breast cancer. Acta Oncol 1992;31:265-70.
25. Leborgne F, Leborgne JH, Ortega B, Doldan R, Zubizarretta E. Breast conservation treatment of early stage breast cancer: patterns of failure. Int J Radiat Oncol Biol Phys 1995;31: 765-75.
26. McCormick B, Hakes T, Yahalom J, Kinne D, Norton L. Breast conserving surgery and radiation: the delay of primary radiation after adjuvant chemotherapy does not influence local control. Proc Am Soc Clin Oncol 1992;11:55.
27. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
28. Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized Phase III trial. J Clin Oncol 1996;15:207-15.
29. Taylor ME, Perez CA, Halverson KJ, Kuske RR, Philpott GW, Garcia DM, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 1995;31:753-64.
30. Markiewicz DA, Schultz D, Haas J, Harris EER, Fox KR, Glick J, et al. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 1996;35:661-8.
31. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996;88:918-22.